042), but not at six months (P=0.198), or nine months (P=0.242). In our site patients with borderline

resectable disease median OS was 16.7 months (95% CI, 12.7-20.4 months) and median MFS was 10.5 months (95% CI, 8.1-14.5 months). In patients with locally advanced disease median OS was 13.7 (95% CI, 10.5-16.1 months) and median MFS was 9.2 months (95% CI, 5.0-13.2 months). OS and MFS were improved in patients with borderline resectable disease compared to locally advance disease by Inhibitors,research,lifescience,medical log-rank analysis (P=0.032 and P=0.039 respectively). There was no difference in LC between patients with borderline resectable and locally advanced disease (P=0.318). On univariable survival analysis, younger patients had improved overall survival (P=0.001) (Table 3). Patients with locally advanced disease had worse overall survival than patients with Inhibitors,research,lifescience,medical borderline resectable disease (HR 1.53, P=0.033). Patients who received chemotherapy followed by chemoradiation therapy and patients who were able to undergo margin-negative resection had better survival (P=0.015, and P<0.001 respectively). Nodal status at diagnosis did not affect overall survival. There was also no difference in survival based on the CA 19-9 level prior to treatment. On multivariable analysis younger age (P=0.009), borderline resectable disease (P=0.035), margin-negative resection (P=0.002), and receiving chemotherapy followed Inhibitors,research,lifescience,medical by chemoradiation therapy (P=0.035) were all associated with

improved OS. Table 3 Cox proportional hazard models for overall survival More patients experienced distant metastasis than local progression

for the overall group, and for all three treatment groups (Table 4). There was no difference Inhibitors,research,lifescience,medical in the overall percent of patients experiencing local progression among the three treatment groups (P=0.46). Isolated local progression without distant metastasis at any time before death occurred in 9 patients (14%) in the C group, 3 patients (13%) of the CRT group, and 4 patients (15%) in the CCRT group (P=0.73). Distant metastasis without local progression at any time before Inhibitors,research,lifescience,medical death occurred in 19 patients (33%) in the C group, 10 patients (43%) of the CRT group, and 11 patients (41%) in the CCRT group (P=0.38). Most distant recurrences occurred in the liver, lung, or peritoneum. Table 4 Sites of failure by treatment group Discussion We report our experience treating a large series of patients with borderline resectable AV-951 and locally advanced pancreatic cancer using three treatment strategies including chemotherapy alone, concurrent chemoradiation therapy, or induction chemotherapy followed by chemoradiation therapy. Patients treated with induction chemotherapy followed by chemoradiation therapy had an improved OS and MFS compared to patients treated with chemotherapy alone. The use of induction chemotherapy followed by chemoradiation therapy was associated with improved survival compared to chemotherapy alone on multivariable survival analysis as well.